This trial is studying how well the combination of these two drugs works in treating patients with NSCLC that has an EGFR mutation.
1 Primary · 6 Secondary · Reporting Duration: 2 years
Experimental Treatment
25 Total Participants · 1 Treatment Group
Primary Treatment: Osimertinib · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: